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SUMMARY
Individuals with major depressive disorder often experience obstructive
sleep apnea. However, the relationship between depression and less
severe sleep-disordered breathing is unclear. This study examined the
rate of sleep-disordered breathing in depression after excluding those
who had clinically signiﬁcant sleep apnea (>5 apneas∙h1). Archival data
collected between 1991 and 2005 were used to assess the prevalence of
sleep-disordered breathing events in 60 (31 depressed; 29 healthy
controls) unmedicated participants. Respiratory events were automati-
cally detected using a program developed in-house measuring thermal
nasal air-ﬂow and chest pressure. Results show that even after excluding
participants with clinically signiﬁcant sleep-disordered breathing, individ-
uals with depression continue to exhibit higher rates of sleep-disordered
breathing compared with healthy controls (depressed group: apnea–
hypopnea index mean = 0.524, SE = 0.105; healthy group: apnea–
hypopnea index mean = 0.179, SE = 0.108). Exploratory analyses were
also conducted to assess for rates of exclusion in depression studies due
to sleep-disordered breathing. Study exclusion of sleep-disordered
breathing was quantiﬁed based on self-report during telephone screen-
ing, and via ﬁrst night polysomnography. Results from phone screening
data reveal that individuals reporting depression were 5.86 times more
likely to report a diagnosis of obstructive sleep apnea than presumptive
control participants. Furthermore, all of the participants excluded for
severe sleep-disordered breathing detected on the ﬁrst night were
participants with depression. These ﬁndings illustrate the importance of
understanding the relationship between sleep-disordered breathing and
depression, and suggest that screening and quantiﬁcation of sleep-
disordered breathing should be considered in depression research.
INTRODUCTION
Over two decades of research and clinical data have linked
symptoms of depression to sleep-disordered breathing (SDB;
for review, see Harris et al., 2009). For example, there is
convincing evidence that individuals diagnosed with obstruc-
tive sleep apnea (OSA) experience more symptoms of
depression than individuals without OSA (Ong et al., 2009;
Schroder and O’Hara, 2005). Furthermore, epidemiological
data indicate that 18% of individuals with major depressive
disorder (MDD) endorse symptoms consistent with breathing-
related sleep disorders (Ohayon, 2003).
While these studies indicate a higher prevalence of
clinically signiﬁcant SDB in individuals with MDD compared
with healthy controls (HC), sub-clinical SDB may also play an
important role in the onset and maintenance of MDD. A
previous study by Deldin et al. (2006) indicated more SDB
events in depressed compared with non-depressed partici-
pants, and predicted accurate diagnostic grouping
(depressed, non-depressed) in 81% of participants using
SDB variables. These ﬁndings may have important implica-
tions in treatment for depression. For example, non-response
to antidepressants may be explained by occult SDB. Addi-
tionally, psychotropic medications such as benzodiazepines
may be contraindicated in individuals with co-occurring SDB.
While screening for SDB (such as OSA) is common practice
in most sleep laboratories, non-sleep-related depression
studies do not commonly screen for SDB. These differences
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in protocol may result in different samples of depressed
subjects, thereby decreasing the generalizability of results,
and may adversely affect the validity of such research. A
more deﬁned understanding of the relationship between SDB
and depression may motivate standard inclusion of SDB
screening in all depression studies and consideration of
treatment for less severe SDB in those with MDD. Studies
support improvement in mood and depressive symptoms
after continuous positive airways pressure (CPAP) treatment
of SDB (Habukawa et al., 2010; Harris et al., 2009). To date,
however, there are only limited data on the impact of SDB on
depression outcomes in those who meet diagnostic criteria
for MDD. The data presented by Deldin et al. (2006) highlight
the importance of SDB in MDD, but the study is limited by the
absence of controlled screening for SDB. Furthermore, SDB
was assessed at home via a portable monitoring device
rather than in-laboratory polysomnography (PSG). The pres-
ent study seeks to address these limitations by assessing the
prevalence of SDB events using in-lab PSG in unmedicated
individuals diagnosed with MDD, and HC. Based on previous
research, it was predicted that those with MDD would show
higher rates of SDB, even after excluding individuals with
clinically signiﬁcant SDB.
MATERIALS AND METHODS
Assessment of SDB was based on archival data collected
by the fourth and ﬁfth authors (R.H. and R.A.) at the
University of Texas Southwestern Medical Center at Dallas
(UTSW) and the University of Michigan (UM) between
1991 and 2005. All participants completed an initial
telephone interview that included screening questions for
depression, which was followed by a clinical interview if no
exclusion criteria were reported. Individuals were excluded
for current shift-work or current sleep disorders (e.g. OSA,
narcolepsy, bruxism).
Individuals enrolled based on phone screening underwent
a Structured Clinical Interview for DSM-IV Axis I Disorders
(Spitzer et al., 1990). The 17-item Hamilton Rating Scale for
Depression quantiﬁed depressive symptom severity (HRSD;
Hamilton, 1960). Participants were included in the HC group
if they reported no personal or family history of psychopa-
thology, and participants were included in the MDD group if
they met criteria for MDD, were in a current depressive
episode and had an HRSD score of at least 17. Exclusionary
criteria included lifetime histories of substance dependence,
bipolar disorder, psychosis, and anorexia or bulimia. All
participants were medication-free for a minimum of 2 weeks.
Participants maintained regular sleep schedules and com-
pleted sleep diaries for 5 days prior to overnight PSG.
All ﬁrst-night PSG recordings were reviewed for clinically
signiﬁcant SDB in individuals who did not endorse symp-
toms of OSA during phone screening. PSG was visually
screened for SDB events by a doctoral-level clinical
psychologist with substantial clinical experience in assess-
ment of SDB. Individuals for whom SDB events were
severe enough to obscure electroencephalogram recording
were screened out. Additional details regarding PSG
recording and data processing can be found in previous
manuscripts (e.g. Armitage et al., 1994). All study proce-
dures were approved by the Institutional Review Boards of
UTSW and UM, and all participants provided informed
consent prior to study participation.
Exploratory analyses assessing rates of exclusion due to
SDB were conducted in two samples. The ﬁrst analysis
assessed exclusion of subjects due to expressed knowledge
of SDB during telephone screens of 4 663 adults. The
second analysis quantiﬁed the exclusion of participants on
the basis of PSG-deﬁned clinically signiﬁcant SDB recorded
on the ﬁrst night in 631 adults who participated in laboratory
sleep and depression studies.
A ﬁnal analysis was conducted to further quantify and
compare the incidence of occult SDB (i.e. that below clinical
threshold) in MDD and HC participants after excluding
individuals with clinically signiﬁcant SDB (>5 apneas∙h1)
based on PSG recordings. A random sample of participants
was selected from the archival database. Files noted for
signiﬁcant SDB or poor signal quality were excluded, result-
ing in a total of 31 MDD and 29 HC participants in the
analysis. Groups did not differ by age or sex (Table 1).
Respiratory events were quantiﬁed using a program devel-
oped in-house to measure the reduction in amplitude of
thermal nasal air-ﬂow (N/O) and chest pressure signals
compared with baseline stable-breathing epochs established
for each individual.
A distinction between standard and sub-clinical hypopnea
events was made in order to capture a range of occult SDB.
Events were classiﬁed as hypopneas (Hp) when a decrease
of 50% or more in N/O and chest signal was detected (Iber
et al. 2007). Events with a 10–50% amplitude reduction in N/
O and chest signals were marked as occult-hypopnea events
(oHp) to represent a sub-clinical range of SDB. All events
lasted for 10 s or longer. Respiratory events were also coded
as either arousals (Ar) or non-arousals (Na) depending on
coincidental increase of alpha waves and body movement,
reﬂecting increased sleep disruption. Epochs containing
artifacts were excluded from analysis. The apnea–hypopnea
Index (AHI; number of events per hour) for all SDB events
was calculated, and subsequently entered as the dependent
variable into a three-way Type (Hp, oHp)9Arousal (Ar, Na)
9Group (MDD, HC) repeated-measures ANOVA.
Table 1 Demographic information by group
MDD HC P
Sex (M:F) 16 : 15 15 : 14 ns
Age (years) 33.32 32.17 ns
F, female; HC, healthy control; M, male; MDD, major depressive
disorder;
ns, not signiﬁcant (P > 0.05).
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RESULTS
Results from the repeated-measures ANOVA revealed higher
rates of disordered breathing events per hour in the MDD
group (AHI mean = 0.524, SE = 0.105) compared with the
HC group (AHI mean = 0.179, SE = 0.108; Group,
F1,58 = 5.270, P < 0.05). Furthermore, results indicated
group differences by type of breathing event (F1,58 = 4.072,
P < 0.05). Post hoc analyses revealed a higher AHI for
hypopneas in MDDs compared with HCs (Type9Group,
F1,58 = 4.744, P < 0.05; Fig. 1). No signiﬁcant effects were
found for arousal.
Additionally, exploratory descriptive analyses examined
reported OSA at phone screening. Results indicated that of
1625 subjects who reported signs of depression, 64 disclosed
a diagnosis of OSA. Chi-square analysis suggested that
although the majority of participants did not report OSA during
phone screening, those with depression were much more
likely to have received a diagnosis of OSA than presumptive
control subjects [ﬁve of 713; v2 (1, N = 2338) = 18.132,
P < 0.001]. Speciﬁcally, participants who screened positive
for depressionwere 5.86 timesmore likely to report a diagnosis
of OSA than controls. Furthermore, all of the participants (14
out of 631 total participants) who were excluded from sleep
studies between 1991 and 2005 due to severe SDB detected
on the ﬁrst night of PSG had been diagnosed with MDD.
DISCUSSION
The primary aim of this study was to delineate the
relationship between SDB and depression using laboratory
PSG. Even after excluding individuals with clinically signi-
ﬁcant SDB through self-report (phone screening) and
ﬁrst-night PSG, those with MDD still exhibited more
ﬂow-limitation events than HCs, suggesting a relationship
between SDB and depression. Group differences were more
notable in hypopneas than in occult-hypopneas, suggesting
that the relationship between disordered breathing and
depression is possibly related to the degree of hypoxia.
Results also suggest that future research should examine
the efﬁcacy of CPAP or other treatments for sub-clinical
SDB in MDD.
These ﬁndings have implications for current standards of
depression research, especially because this sample was
derived within a research context. While sleep research on
depression routinely excludes for diagnosable OSA, most if
not all do not account for sub-clinical levels of SDB. Results
showing group differences based on the decrease of airﬂow,
rather than subsequent arousals, further support hypoxia as
an important variable in the relationship between SDB and
depression. Adopting a dimensional approach to SDB may
be a better way of characterizing the relationship between
MDD and SDB.
LIMITATIONS
Limitations of the current study include the use of archival
data from studies that were not originally designed to assess
SDB. Other limitations include the small sample size and a
lack of pressure transducer data to conﬁrm the nature of the
disordered breathing events.
CONCLUSIONS
This study revealed higher levels of SDB in MDD, even after
excluding individuals with clinically signiﬁcant SDB. This
result suggests that screening and quantiﬁcation of SDB
should be standard practice in depression research and
clinical care.
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Figure 1. Individuals with major depressive disorder (MDD) exhibit
more breathing events per hour compared with healthy controls (HC).
The difference is most pronounced for hypopnea events. Error bars
represent one standard error. AHI, apnea–hypopnea index.
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